University of Miami initiates clinical trial of XM-ONE®

The transplantation unit at Jackson Memorial Hospital and the University of Miami, FL, USA has entered into a research project with the Allenex group company AbSorber. The project is a pilot study evaluating the endothelial cell cross match XM-ONE® in their Living Donor program. University of Miami will investigate if antibodies detected by XM-ONE® will affect the outcome for the individual patient, in pre- and post-transplant situations.

Corrected name: Dr Giselle Guerra. This news item sent first time June 7.

“Non-HLA antibodies, especially endothelial cell antibodies, play a significant role as risk markers of acute rejection in kidney transplant recipients” says Dr. Giselle Guerra, MD at the University of Miami and principal investigator of the study. “However, the post-transplant risk evaluation of these antibodies have not been studied and we are excited to have this possibility”, she continues.

This prospective pilot study will include 138 patients and is estimated to have an enrollment period of two years. Patients will thereafter be monitored for six months post transplantation.

“The last years a number of researchers have published important data on the relevance of non-HLA antibodies as well as XM-ONE® used for risk assessment in a pre-transplant setting. An obvious next step is to investigate the presence and importance of non-HLA antibodies post-transplantation using XM-ONE®. We are proud that Dr. Guerra and her co-workers at Jackson Memorial Hospital approached us to perform this important study”, says Anders Karlsson, CEO of Allenex..

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph.: +4670-918 0010, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on June 8, 2012, at 10.01 CET.

Allenex is a life science-company that develop, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.